Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02624180 · ClinicalTrials.gov registry record · Phase 2
Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV
A Phase 2 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT02624180: Completed Phase 2 study, sponsored by Johns Hopkins University.
NCT02624180 is a Phase 2 study that has completed, run by Johns Hopkins University. The registered enrollment target is 81 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02624180, a Phase 2 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
The investigators are studying whether an anti-inflammatory intervention improves impaired coronary endothelial function (CEF) in HIV+ people with no clinical coronary artery disease (CAD).
Interventions
- DRUG Placebo
- DRUG Colchicine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2015-11 |
| Est. Completion | 2020-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02624180
The ClinicalTrials.gov registry entry for NCT02624180 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02624180 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02624180 about?
NCT02624180 is a clinical study titled "Inflammatory Pathogenesis of Coronary Atherosclerosis in HIV". The investigators are studying whether an anti-inflammatory intervention improves impaired coronary endothelial function (CEF) in HIV+ people with no clinical coronary artery disease (CAD).
What is the current status of trial NCT02624180?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2015-11. Estimated completion is 2020-09-01.
What interventions are being tested in trial NCT02624180?
The interventions under investigation include: Placebo (DRUG), Colchicine (DRUG).
Who is sponsoring clinical trial NCT02624180?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.